The effects of Dapagliflozin on monocyte-HDL ratio and neutrophil-lymphocyte ratio among patients with type-2 diabetes mellitus.

The present study attempted to explore the effects of starting dapagliflozin for glycemic control in Type-2 diabetes mellitus (DM) patients on the monocyte high-density lipoprotein ratio (MHR) and neutrophil-leukocyte ratio (NLO) as oxidative and inflammation markers.We retrospectively investigated the medical files of Type-2 DM patients administered dapagliflozin for at least 12 weeks. Then, we recorded the patients' demographics and compared their pre- and post-treatment biochemical and hemogram parameters.We retrospectively evaluated the data of 210 patients. The results revealed that the levels of fasting blood glucose (FBG; p < 0.001), hemoglobin A1c (HbA1c; p < 0.001), high-density lipoprotein cholesterol (HDL-c; p = 0.011), triglyceride (p = 0.002), and monocytes (p = 0.019) and MHR (p < 0.001) significantly decreased among the patients following dapagliflozin treatment when compared to the pre-dapagliflozin period.MHR is considered a practical, inexpensive inflammation marker for diabetics using dapagliflozin. However, we could not conclude NLR to be a significant inflammation marker, which, in turn, may suggest the need for comprehensive, prospective research.